Iberis single-electrode RDN system has been registered in the European Union and is the first product of its kind in Asia.
Bioheart BRS project obtained the subsidy from Pudong New Area "Technology Development Innovation Fund Biotech Project".
AngioCare was awarded as Shanghai High-tech Enterprise;
Bioheart BRS products received funding from the "Science and Technology Innovation Action Plan" of the Shanghai Municipal Science and Technology Commission
Iberis multi-electrode RDN system has been registered in the European Union.
Iberis multi-electrode RDN system entered the special approval channel for innovative medical devices;
BRS product obtained special fund subsidy for the development of strategic new industries from the Shanghai Development and Reform Commission;
Bioheart BRS product passed the special approval application for innovative medical devices of the State Food and Drug Administration, and entered the special approval procedure "green channel";
AngioCare was evaluated as a pilot unit for patent affairs in Shanghai.
AngioCare was awarded as Shanghai High-tech Enterprise again.
